C4 Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-02-18: Study NCT07284758; Company role Lead sponsor; Phase Phase 2; Status Recruiting.
- 2026-02-06: Study NCT07280013; Company role Lead sponsor; Phase Phase 1; Status Recruiting.
- 2022-12-08: Study NCT05668585; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2022-03-25: Study NCT05355753; Company role Lead sponsor; Phase Phase 1; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-02-18 | NCT07284758 A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | Lead sponsor | Phase 2 | Recruiting | Multiple Myeloma; Relapsed/Refractory Multiple Myeloma | 100 | 2030-03 |
| 2026-02-06 | NCT07280013 A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | Lead sponsor | Phase 1 | Recruiting | Multiple Myeloma (MM) | 60 | 2029-06 |
| 2022-12-08 | NCT05668585 A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | Lead sponsor | Phase 1 | Completed | Solid Tumors; Melanoma; NSCLC; CRC; ATC | 89 | 2025-11-05 |
| 2022-03-25 | NCT05355753 A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | Lead sponsor | Phase 1 | Terminated | Synovial Sarcoma; Soft Tissue Sarcoma | 49 | 2023-12-19 |
| 2021-04-27 | NCT04756726 Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | Lead sponsor | Phase 1 | Active not recruiting | Multiple Myeloma; Lymphoma, Non-Hodgkin's | 224 | 2026-12-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |